Table 2 Patient baseline demographic and clinical characteristics in the radionecrosis population and in the population without radionecrosis
From: Stereotactic radiotherapy for brain metastases: predictive factors of radionecrosis
Characteristic | Radionecrosis (n = 17) | No radionecrosis (n = 106) | p value§ |
|---|---|---|---|
Age, median [range] years old | 60 [44–74] | 66 [37–85] | 0.032 |
Sex, n (%) | |||
Male | 6 (35.3) | 57 (53.8) | 0.16 |
Female | 11 (64.7) | 49 (46.2) | |
ECOG performance status, n (%) | |||
0–1 | 17 (100) | 85 (80.2) | 0.22 |
2–3 | 0 | 14 (13.2) | |
Unknown | 0 | 7 (6.6) | |
Cancer type, n (%) | |||
ADK | 14 (82.4) | 86 (81.1) | 1 |
Other | 3 (17.6) | 20 (18.9) | |
Primary site, n (%) | Lung vs Other | ||
Lung | 12 (70.6) | 68 (64.2) | 0.61 |
Breast | 2 (11.8) | 16 (15.1) | |
Renal | 1 (5.9) | 7 (6.6) | |
Digestive | 1 (5.9) | 9 (8.5) | |
Other | 1 (5.9) | 6 (5.7) | |
Number of treated metastases, n (%) | |||
1 | 15(88.2) | 64 (60.4) | 0.026 |
>1 | 2 (11.8) | 42 (39.6) | |
Mutations, n (%) | |||
Yes | 6 (35.9) | 32(30.2) | 0.67 |
No | 11 (64.7) | 74(69.8) | |
Treatment history, n(%) | |||
Chemotherapy | 8 (47.1) | 68 (64.2) | 0.18 |
Stereotactic Radiotherapy | 2 (11.8) | 9 (8.5) | 0.65 |
Immunotherapy | |||
Radiotherapy | 6 (35.3) | 25 (23.6) | 0.37 |
Targeted therapy | 6 (35.3) | 54 (50.9) | 0.23 |
Hormonotherapy | 1 (5.9) | 13 (12.3) | 0.69 |
Comorbidities, n (%) | |||
Yes | 3 (17.6) | 49 (46.2) | 0.027 |
No | 14 (82.4) | 57 (53.8) | |
Treatment during SRT, n (%) | |||
Chemotherapy | 2 (11.8) | 10 (9.4) | 0.67 |
Immunotherapy | 1(5.9) | 8 (7.5) | 1 |
Corticotherapy | 15 (88.2) | 87 (82.1) | 0.47 |
Levetiracetam | 10 (58.8) | 51 (48.1) | 0.41 |
SRT spread, n (%) | |||
≤ 4 days | 7 (41.2) | 47 (44.3) | 0.81 |
≥ 5 days | 10 (58.8) | 59 (55.7) | |
Post-operative or initial treatment, n(%) | |||
Initial | 10 (58.8) | 77(72.6) | 0.23 |
Post-operative | 7 (41.2) | 25(23.6) | |
Both | 0 | 4(3.8) | |
Metastases location, n(%) | |||
Frontal | 5 (29.4) | 50 (47.7) | 0.17 |
Parietal | 2 (11.8) | 35 (33.0) | 0.08 |
Occipital | 3 (17.6) | 17 (16.0) | 1 |
Temporal | 5 (29.4) | 19 (17.9) | 0.32 |
Cerebellum | 2 (11.8) | 28 (26.4) | 0.24 |
Other | 3 (17.6) | 1 (0.9) | 0.17 |
PTV | |||
Median [range], cm3 | 9.1 [1.3–69.6] | 8.25 [1.1–87.4] | 0.56 |
Irradiated healthy brain volume | |||
Median [range], cm3 | 1321.6 [1191.3–1686.2] | 1319.55 [1058.8-1661.6] | 0.7 |
SRT doses (Gy), n(%) | |||
3 × 11 Gy | 10 (58.8) | 72 (67.9) | ≥ 30 Gy vs ≤ 27 Gy 0.37 |
3 × 10 Gy | 0 | 2 (1.9) | |
3 × 9 Gy | 2 (11.8) | 6 (5.7) | |
3 × 8 Gy | 5 (29.4) | 26 (24.5) | |
SRT-diagnostic BM delay, | |||
Median [range], days | 44 [15–262] | 43.5 [13–507] | 0.82 |